. (2015) Programmed cell death 6 interacting protein (PDCD6IP) and Experimental design -Initial assessment was performed using urines from 60 control and 60 uGI cancer patients by MS to establish a peak-pattern or fingerprint model, which was validated by a further set of 59 samples.
Introduction
Malignant tumours of the upper gastro-intestinal (uGI) tract are a significant cause of cancer-related death worldwide. Gastric cancer is the fourth most common cancer globally (approximately 8% of all cancer cases) and the second most common cause of cancer-related death [1] . Oesophageal cancer is the sixth most common cancer worldwide [2] . It affects twice as many males than females, amounts to approximately 4% of all cancer cases and 5% of all cancer related deaths, and has a 5-year survival rate of only 13% [3] . In comparison, pancreatic cancer has one of the lowest survival rates of all (16% at one year following diagnosis which drops to 3% by 5 years). In Western populations, pancreatic cancer contributes 3% of all diagnosed cancer cases and 5% of all cancerrelated deaths [4] .
The incidence of gastric cancer has been falling continually over the last few decades [5] , but the incidence rates of pancreatic and oesophageal cancers globally have shown a worrying increase [6, 7] . The development of various therapeutic strategies, based either on improved surgical techniques or neo-adjuvant/adjuvant chemotherapy has improved survival rates but only in the order of a few percent [8] [9] [10] . One of the main reasons for this is that most cases are diagnosed at an advanced stage. As a consequence, it is of utmost importance to develop methodologies to diagnose the onset of malignancy as soon as possible, preferably prior to the development of clinical symptoms.
Currently, there is a clear lack of accepted clinical molecular markers which can be used reliably to assess for the presence of malignancy [11] . The most successful and clinically widely used assay for pancreatic cancer is serum biomarker CA19.9. However, its use is limited by poor sensitivity in symptomatic patients (only 80%), false negative -5 -results of 5-10% in the Lewis negative phenotype [12] , and increased false positive rates of 10-60% in the presence of obstructive jaundice [13] . CA19.9 can not be used for screening asymptomatic populations [14] , and its specificity to diagnose pancreatic cancer in symptomatic patients ranges from 82 to 90% [15] . Results using commercial sources of CA19.9 assays are not interchangeable, and show very poor usability for other tumour types such as gastric cancer, with detection rates of 3 to 38% [16] . A more suitable pan-cancer biomarker was identified as CA215, which, like CA19.9, consists of carbohydrate-associated epitopes of proteins, but the positive predictive values were shown to be very low, ranging from 38 to 83% across a number of common cancer types [17] . Recent studies have focused on micro RNA, where elevated quantities of miR-222 in diseased tissue could be associated with pancreatic cancer and poor prognosis [18] . A potential complementary set of biomarkers for gastric cancer was recently identified as V-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL) and miR-126 [19] , and legumain (LGMN) was described to be associated with poor prognosis and metastasis [20] . Oesophageal cancer biomarkers were identified as phospholipase A2 group IIA (PLA2G2A) [ There is a current trend to use a combination of several markers to assess tumour growth for diagnostic and prognostic purposes. An improvement in CA19.9 applicability -6 -for pancreatic cancer detection involves the combination of several additional biomarkers, such as regenerating islet-derived 1 beta (REG1B), syncollin (SYCN), anterior gradient homolog 2 protein (AGR2), and lysyl oxidase-like 2 (LOXL2) [40] . An extension of this approach involves the multiplexing of many different targets simultaneously using antibody-arrays [41, 42] or quantum dot technologies [43] .
Initial studies using transcriptomic and genomic array screens of tissue biopsies have shown promise in defining potential biomarkers and response to personalised chemotherapy (reviewed in e.g. [44] [45] [46] ). However, these studies require invasive methods to obtain tissue, and currently remain at the experimental phase. For this reason, a focus on non-invasive sampling techniques may be beneficial. One medium of choice is serum, but since proteolytic fragmentation and degradation of biomolecules by endogeneous proteases can occur during or after sample collection [47, 48] , this approach poses obstacles that might be difficult to standardise. Population heterogeneity and genetic variation can also have an unexpected impact on the implementation of biomarker screening assays, and therefore there is a need to simplify the screening medium. Urine, which contains approximately 4000 to 5000 proteins [49] [50] [51] (compared with at least 10000 in blood [52] ), offers a (usually) unlimited quantity of a viable alternative. Urine is also relatively stable in protein/peptide composition and fragmentation state [53, 54] , even after prolonged storage [55] .
In this study, we have used a combination of mass spectrometric techniques to analyse urine samples from a cohort of uGI cancer patients and non-cancer controls, in order to define peptide fingerprint profiling patterns and then perform independent protein expression profiling. Both sets of results were subsequently combined using -7 -bioinformatics tools to uncover significantly altered potential biomarkers, of which several were then validated by an independent technique. Additionally, we assessed whether there was a correlation of these markers with a plasma marker of inflammation, namely C-reactive protein (CRP). Similar procedures were employed in a previous study [30] , where a cation-exchanger was used to clean and enrich urinary proteins and peptides (CM10 chip). This approach, in essence, focussed on medium to high abundance molecules present in human urine. In the present study, we focussed on low-abundance molecules using metal chelate affinity chromatography (IMAC30 [Cu 2+ -complexed] chip).
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Materials and methods
The Methods were carried out according to our protocols published previously [30]. M NaHAc pH4 and washed with water, followed by two washes with binding buffer (0.1 M NaHPO 4 , 0.5 M NaCl), and then processed in a bioprocessor-assembly by incubating 0.1 ml urine and 0.1 ml binding buffer for 1 hour at room temperature with vigorous shaking, followed by three washes with 0.2 ml binding buffer for 5 minutes at room temperature with vigorous shaking, and two washes with 0.2 ml water at room temperature with vigorous shaking. The chips were removed from the bioprocessor assembly, air-dried and 2 times 1 µl energy-absorbing matrix (SPA, in 50% ACN, 0.5% TFA) was added. Air-dried chips were analysed in a PCS4000 SELDI-TOF instrument (Bio-Rad, Hemel Hempstead, UK) by measuring the 1000-25000 Da range with a laser setting of 2.5 µJ. Spectra were exported as '.xml' files. The SELDI instrument was calibrated using the ProteinChip All-In-one peptide standard (Bio-Rad, Hemel
Hempstead, UK). Source voltage was 25000 V, and detector voltage was 2946 V. Quality control and consistency were ensured by using one random pool of urines on one spot per chip. Spectra of the full analysis (179 cohort samples, 26 quality control samples, 410 spectra in total) were recorded in two large batches to minimize instrument variability and drift. Spectral alignments of all quality controls ensured consistency of all spectra.
Data processing. ProteinChip Data Manager Software (PCDMS) version 4.1 with
integrated Biomarker Wizard cluster analysis (Bio-Rad, Hemel Hempstead, UK) was used for analysis. SELDI-TOF-MS traces were split into control and cancer groups. The -10 -baseline was subtracted from individual m/z traces and profiles were normalised using total ion current, followed by identification of peak clusters using the cluster analysis tool. In the first pass, peaks were selected where the signal to noise (S/N) ratio was >5, and valley depth was >3, and in the second pass, S/N >2 and valley depth >2. The cluster mass window was set to 0.2% of mass. Clustered peaks were only included if they occurred in at least 10% of all spectra. The resulting p-values, ROC areas, average and median m/z values, and intensities of the clustered peaks were exported and saved as '.csv' files and used for model building. Heat-maps using Pearson's correlation and principle component analysis (PCA) plots were calculated to assess global group divisions (i.e. cancer and control). A two-sample t-test was used to compare mean normalized intensities between the case and control groups. The p-value was set at 0.05 to be statistically significant.
Model building and validation. Clustered peak lists were analysed with the
Biomarker Pattern Software (BPS) (Bio-Rad, Hemel Hempstead, UK). m/z versus intensity matrices were analysed using decision tree-analysis, selecting the standard error rule of minimum cost-tree regardless of size, and the method used was Gini. V-fold testing was set to 1000. 60 cancer samples and 60 control samples were randomly chosen and used as the learning and testing dataset. The remainder of 59 samples was used as the validation dataset for blind-testing. Sensitivity was defined as the probability of predicting cancer cases, and the specificity was defined as the probability of predicting control samples.
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Peak isolation and identification.
Peaks observed in the IMAC30 chip-type (see Supplementary Table 2 ) that showed marked expression differences between control and cancer samples, and were branching points in the model (see Table 2 Mascot hits with a false discovery rate <0.05 were taken into consideration.
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Mascot-SELDI matrix matching.
Observed proteins with at least two peptide matches from the LC-MS/MS analysis were then further analysed by pattern matching based on SELDI-TOF-MS measured expression levels of peaks of interest (expected abundance in selected samples). This was done using software written in-house, which compares observed protein expression patterns in a pre-defined set of samples (LC-MS/MS results) against a matrix of peak patterns (SELDI-TOF clustered peak intensities, where estimated peaks are set to null) in the same set of samples. The scoring is based on sensitivity (percent observed over expected) and specificity (percent not observed over not expected), and results are presented in descending order of cumulative scores. The distribution of identified peptides within a protein, as well as calculated molecular mass of identified proteins, were also used to assess whether breakdown products were likely to account for mass variances between the expected mass and the molecular weight of the full length protein. (ab56932) (AbCam, Cambridge, UK) (used at a dilution of 1:1000); rabbit-anti-human serum albumin (Sigma-Aldrich, Gillingham, UK) (used at a dilution of 1:1000); and peroxidase-coupled secondary antibodies were from Upstate (Lake Placid, NY, U.S.A.)
Validation of
(used at a dilution of 1:5000). Detection of signals was by chemiluminescence using ECL Western blotting reagents (Thermo Fisher Scientific, Cramlington, UK).
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Results
We collected mass spectra in the m/z range of 1000 to 25000 for the 179 patient urine samples. The full peak list used in PCDMS data analysis is shown in Supplementary Figure 1 ), but we distinct enough to allow a degree of separation in heat-map plotting using Pearson's correlation.
Decision-tree modelling using the Biomarker Pattern software (BPS) of peak clusters (see Supplementary Table 3 for raw input data and group dividers) of 60 random samples of each cohort was validated by the remainder of the entire cohort (33 control and 26 cancer samples). The decision tree model is shown in Figure 1A , and in more detail in Supplementary Figure 2 . The validation data-set showed a sensitivity of 85% and a specificity of 79% with an overall correctness of 81%, and application of the derived model to the entire cohort showed a sensitivity of 88%, specificity of 91% and an overall correctness of 90%. Statistical analysis of the five m/z cluster peaks implicated in the model is shown in Table 2 . Two of the candidate targets at m/z 3589 and 13387 displayed down-regulation in cancer, whereas m/z 2577, 5646 and 7477 peak clusters showed a cancer-associated up-regulation. All potential markers were statistically -15 -significant (p<0.05). Expression analysis using box-and-whisker-plots of these five lead candidates is shown in Figure 1 , panels B to F.
We then evaluated whether we inadvertently biased our model-prediction towards a specific cancer type, and could show that two major cancer types in our cohort (oesophagus and pancreas) were distributed equally (see Supplementary Figure 3 ).
Additionally, we could not detect an age-dependency or age-covariance of any of the This is most likely due to low expression levels in the sample even after IMACchromatographic enrichment, which was also evident by the low intensity values observed by SELDI mass spectrometry ( Table 2 
Discussion
Urine is arguably the best biological substrate for biomarker development in the clinical setting, as it is relatively stable and easily obtainable in large quantities through non-invasive sampling. Previous studies have found SELDI-TOF-MS to be ideally suited for urine analysis, as it combines speed and high throughput with relatively low cost [56] . The main disadvantage of SELDI-TOF-MS is the medium resolution of the spectra obtained. However, this technique is able to resolve peaks in the 1000-25000 Da range from spectra with less than 500 peaks. We found that the IMAC30 chip, and previously the CM10 chip [30] , are both useful chip-types for the analysis of human urine, and we were able to generate models based on the full analysis of 179 uGI cancer and non-cancer samples. Using the tree-analysis method, we established a statistical model with an overall sensitivity of 88% and specificities of 91% across the entire datasets. Using expression pattern matching, we could assign several proteins identified in urine to our proposed biomarkers. These sensitivities and specificities are superior to those exhibited by established serum uGI cancer markers, such as CA 19-9 used in the diagnosis of pancreatic cancer (sensitivity of about 79-81% and a specificity of about 82-90%) [57] .
Larger prospective studies are required to investigate whether theses statistical models can be used effectively in clinical practice.
GFAP is a marker for glioblastoma, where serum levels are substantially elevated compared to healthy controls in whom the molecule is practically undetectable [58] . Our observed up-regulation of GFAP in urine from uGI cancer patients would indicate that this protein is not restricted to glioblastoma, but might be a more general marker of malignant disease. We could also detect a down-regulation in uGI cancer samples for -18 -S100A8. It was reported that the serum levels of S100A8 were marginally reduced in cancer patients [59] , which is similar to our observed down-regulation of the S100A8 associated m/z 3589 cluster. The presence of members of the S100 gene family, including S100A9, in our screen is not entirely surprising. The up-regulation of this protein in cancer has already been documented in our previous study and was validated using
Western blotting [30] . Neuron navigators 1 to 3, which are cytoskeletal regulators that track microtubules, belong to a molecular class that can reorganize the cytoskeleton and induce neurite outgrowth and axonal elongation [60] . Neuron navigator 2 was found to be a retinoic-acid response-element in neuroblastoma [61] , and Neuron navigator 3 was reported to be a cancer-associated molecule that contributes to the pathogenesis of some basal and squamous cell cancers [62] . However, based on our peptide sequence identification, it is likely that we observed only one of these three molecules, but due to sequence similarities we cannot distinguish between them in our analysis.
Importantly, we were able to validate two of our potential biomarkers through Western blotting, namely Rabenosyn-5 and PDCD6IP. Rabenosyn-5 (ZFYVE20) is a Rab GTPase that was reported to be involved in endosomal trafficking, including a role in the lysosomal trafficking of cathepsin D from the Golgi apparatus to lysosomes [63] .
Programmed cell death 6-interacting protein (PDCD6IP), also termed AIP1 or Alix, has a described role in actin filament bundling and endosomal sorting, and mediates extracellular integrin-mediated cell adhesions [64] . Our measured up-regulation, both by MS and by Western blotting, could be an indicator of impending metastasis within the cancer patients.
-19 -It is noteworthy that all of the postulated peak markers in the present study were fragments, unlike the proteins we identified in the CM10 chip-type based cancer dataset [30] . This phenomenon could be due to chromatography-resin properties, where smaller polypeptides were favoured over larger ones, or biochemical/biological reasons, such as fragmentation states of low abundance molecules.
Systemic inflammation (as evidenced by an elevated plasma CRP level [65, 66] ) is a common finding in patients with cancer (where it plays a role in the aetiology of cachexia and cancer-associated anorexia), and can be a confounding factor in biomarker discovery [67] . However, others have failed to find such an association [68] . In this study, we could not detect any correlation between biomarkers, cancer types and CRP, a robust serum marker of systemic inflammation.
In conclusion, we could demonstrate several potential urinary uGI cancer markers using mass spectrometry techniques, bioinformatics data processing, and Western blotting. Most of these markers were up-regulated (rather than down-regulated) in the urinary proteome in association with cancer. Further work is required before such biomarkers can be utilised in the clinical setting. Firstly, larger prospective studies, with the possible inclusion of anti-cancer intervention, will help determine biomarker validity.
Secondly, the development of rapid, high-throughput assays (such as ELISA) for confirmed biomarkers will aid the day-to-day employment of biomarker measurement in the clinical setting. It is also worth mentioning that a simultaneous screen of several markers, as opposed to decision-making using a single biomarker, will undoubtedly expand the usability, accuracy, sensitivity and specificity in clinical diagnosis of uGI cancers as has been shown in assessing pancreatic cancer [69] . Lastly, further studies to 25. Melle, C., Ernst, G., Schimmel, B., Bleul, A., von, E. F., Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca(2+)-binding proteins S100A6 and S100A11. PLoS One 2008, 3 (12), e3767.
-24 - were calculated using the Mann-Whitney test, and the receiver-operating characteristic (ROC) area with cancer as the positive group. The average and median fold change was calculated using intensity values of individual peak clusters from the cancer and control groups. Frequency % describes the likelihood of a particular peak to be found in a specific group by peak-clustering using a S/N of 5. Sensitivity and specificity values were calculated by computational decision-tree modelling using the peak in question as the sole predictor, and the SELDI normalised cut-off values are the associated mass spectrometric intensity values where the reported sensitivity and specificity levels are met. The model score is derived from the tree-analysis modelling of the entire cohort and describes the importance of a peak within the model. Mascot scores, number of peptides found, emPAI, % sequence coverage, and the expected % sequence coverage, based on molecular mass and the m/z, are listed. 
